Background The 2023 International Federation of Gynecology and Obstetrics (FIGO) staging system includes lymphovascular invasion quantification as a staging criterion for endometrioid endometrial carcinomas; no lymphovascular invasion and focal invasion (≤4 vessels involved) are grouped as one category, and substantial invasion as another. Objective To assess the association between lymphovascular invasion and oncologic outcomes. Methods We retrospectively identified patients with FIGO 2009 stage I endometrioid endometrial cancer treated surgically with total hysterectomy and lymph node assessment at two tertiary care centers between January 1, 2012, and December 31, 2019. Lymphovascular space invasion was categorized as focal (<5 vessels involved), substantial (≥5 vessels involved), and no lymphovascular invasion using WHO criteria. Results Of 1555 patients included, 65 (4.2%) had substantial, 119 (7.7%) had focal, and 1371 (88.2%) had no lymphovascular invasion. Median age was 64 years (range 24–92). Thirty-five patients (53.8%) with substantial, 44 (37%) with focal, and 115 (8.4%) with no lymphovascular invasion had stage IB disease (p<0.001); 21 (32.3%) with substantial, 24 (20.2%) with focal, and 91 (6.6%) with no lymphovascular invasion had grade 3 disease (p<0.001). Thirty-six patients (55.4%) with substantial, 80 (67.2%) with focal, and 207 (15.1%) with no lymphovascular invasion received adjuvant treatment (p<0.001). Median follow-up was 61.5 months (range 0.8–133.9). Five-year progression-free survival rates were 68.7% (substantial), 70.5% (focal), and 90.7% (no invasion) (p<0.001). On multivariate analysis, any lymphovascular invasion was associated with increased risk of progression/death (adjusted HR (aHR)=1.84 (95% CI 1.73 to 1.96) for focal; 2.17 (95% CI 1.96 to 2.39) for substantial). Compared with focal, substantial lymphovascular invasion was associated with an aHR for disease progression of 1.18 (95% CI 1.00 to 1.39). Conclusions Focal and substantial lymphovascular invasion were associated with increased risk of disease progression and do not appear to be prognostically distinct. Focal versus no lymphovascular invasion have different prognostic outcomes and should not be combined into one category.
28 March 2026 in International Journal of Gynecological Cancer
Cervical cancer is the third most common gynecologic malignancy in the United States. Traditionally, a radical hysterectomy with bilateral salpingo-oophorectomy with lymph node assessment had been the standard of care; however, there has been a recent shift towards less radical surgery with the establishment of the oncologic safety of conization (as fertility preserving surgery), and simple hysterectomy for certain subgroups of patients with early-stage disease. In addition, uptake in the utilization of sentinel lymph node mapping, compared to systematic lymphadenectomy, has translated to improved perioperative outcomes. While laparotomy is the preferred mode of surgery for patients with cervical cancer, emerging data suggest that protective maneuvers may not compromise oncologist outcomes and multiple clinical trials are evaluating the oncologic safety of minimally invasive surgery. In this present review, we summarize recent advances in surgical management in patients with cervical cancer.
25 April 2026 in International Journal of Gynecological Cancer
The International Federation of Gynecology and Obstetrics 2023 endometrial cancer staging system includes 21 sub-stages and proposes a shift from pure anatomical staging to an approach incorporating histology, grade, lymphovascular invasion, and molecular classification. We sought to evaluate the overall survival prognostic ability of the International Federation of Gynecology and Obstetrics 2023 endometrial cancer staging system compared with the International Federation of Gynecology and Obstetrics 2009 system. We collected clinicopathologic characteristics, molecular profiling results, and survival outcomes for all patients with a new diagnosis of endometrial cancer treated at our institution between 2016 and 2020. All cases underwent pathology review by a gynecologic pathologist at our institution. An International Federation of Gynecology and Obstetrics 2009 and 2023 stage was assigned. We applied R2ϵ statistics based on an isotonic proportional hazards model to compare prognostic ability between the 2 staging systems. Of 2067 patients with endometrial cancer, 952 (46%) underwent tumor molecular profiling. When comparing International Federation of Gynecology and Obstetrics 2009 and 2023 staging, 538 (26.0%) patients were upstaged and 100 (4.8%) were downstaged in the 2023 system. Five-year overall survival estimates were similar across most stages between the 2 staging systems, with some exceptions: the International Federation of Gynecology and Obstetrics 2023 IA3 sub-stage demonstrated improved outcomes (100% vs 70.3% for International Federation of Gynecology and Obstetrics 2009 IIIA) and the IICmp53abn group had poorer prognosis (73% vs 86.8% for International Federation of Gynecology and Obstetrics 2009 II). Using isotonic proportional hazards regression models, the 2023 model slightly numerically outperformed the 2009 model for overall survival (R2ϵ 0.546 vs 0.415); however, adjusted 95% confidence intervals were under-developed. Using a real-world, large, well-annotated cohort of patients with endometrial cancer with expert pathology review, we were able to calculate 5-year progression-free and overall survival rates for each sub-stage. The International Federation of Gynecology and Obstetrics 2023 model demonstrated slightly improved prognostic discrimination compared with the International Federation of Gynecology and Obstetrics 2009 model; however, small patient numbers in each sub-stage and concerns regarding over-fitting limit this analysis.